After US approval, Japan okays its first Alzheimer's drug | The Business Standard
Skip to main content
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Sunday
July 13, 2025

Sign In
Subscribe
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
SUNDAY, JULY 13, 2025
After US approval, Japan okays its first Alzheimer's drug

World+Biz

26 September, 2023, 03:30 pm
Last modified: 26 September, 2023, 04:56 pm

Related News

  • Khaleda urges govt to ensure advanced treatment for singer Farida Parveen
  • Trump unveils 25% tariffs on goods from Japan, S Korea in letters to leaders
  • Japan braces for more quakes, authorities dismiss doomsday hype
  • Japan sets new internet speed record at 402Tbps using standard fibre optics
  • CA urges Japan to enhance cooperation with Bangladesh

After US approval, Japan okays its first Alzheimer's drug

According to the Japanese health ministry, Japan's number of dementia patients who are 65 years of age or older will rise to 7 million in 2025, from the current 6 million.

26 September, 2023, 03:30 pm
Last modified: 26 September, 2023, 04:56 pm
Photo: UNB
Photo: UNB

Japan's health ministry has approved Leqembi, a drug for Alzheimer's disease that was jointly developed by Japanese and US pharmaceutical companies. It's the first drug for treatment of the disease in a country with a rapidly ageing population.

Developed by Japanese drugmaker Eisai Co. and US biotechnology firm Biogen Inc., the drug's approval in Japan comes two months after it was endorsed by the US Food and Drug Administration.

Leqembi is for patients with mild dementia and other symptoms in the early stages of Alzheimer's disease, and the first medicine that can modestly slow their cognitive decline.

The Business Standard Google News Keep updated, follow The Business Standard's Google news channel

Prime Minister Fumio Kishida, who announced Japan's approval of Leqembi on Monday, called it "a breakthrough" and said that the "treatment of dementia has now entered a new era."

Kishida has pledged to step up support for the growing number of dementia patients and their families and is due to launch a panel this week to discuss measures for a dementia-friendly society.

According to the Japanese health ministry, Japan's number of dementia patients who are 65 years of age or older will rise to 7 million in 2025, from the current 6 million.

The drug, however, does not work for everyone and — as with other Alzheimer's drugs that target plaques in the brain — can cause dangerous side effects such as brain swelling and bleeding in rare cases.

Eisai said it will conduct a post-marketing special use survey in all patients administered the drug until enough data is collected from unspecified number of patients under Japanese health ministry procedures.

The drug will be partially covered by health insurance and is expected to be ready for clinical use by the end of the year. The price is yet to be decided but is expected to be expensive, Kyodo News agency reported.

Eisai is committed to delivering Leqembi to people who need it and their families "as a new treatment," said Haruo Naito, the company's CEO.

"We aim to create impact on issues surrounding dementia in Japanese society," he said.

Top News

Alzheimer's Disease / Japan / treatment

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Home Affairs Adviser Lieutenant General (retd) Jahangir Alam Chowdhury at the 11th meeting of the Advisory Council Committee on Law and Order on Sunday, 13 July 2025. Photo: TBS
    Combing operation from now on to catch identified criminals, improve law & order: Home adviser
  • Representational image/Collected
    Mitford murder: 2 more accused arrested
  • Photo shows the twelfth day of the National Consensus Commission’s meeting with political parties at the Foreign Service Academy in Bailey Road, Dhaka on Sunday, 13 July 2025. Photo:TBS
    Consensus reached on emergency declaration reform

MOST VIEWED

  • RAB Director General AKM Shahidur Rahman speaks at the press briefing on a fake bomb threat on Biman Bangladesh flight on Saturday, 12 July 2025. Photo: TBS
    Mother faked bomb threat on Biman flight to stop married son from flying with girlfriend: RAB
  • Bangladeshi garment workers make clothing in the sewing section of a factory in Gazipur, Bangladesh, April 9, 2025. Photo: REUTERS/Mohammad Ponir Hossain/File Photo
    Some Walmart garment orders from Bangladesh on hold due to US tariff threat
  • Infographic: TBS
    Dollar price plummets by Tk2.9 in a week as demand wanes
  • Bangladesh and US hold tariff talks on 11 July 2025. Photo: CA Press Wing
    Dhaka, Washington yet to agree on 20% of US tariff conditions: BGMEA
  • Infograph: TBS
    Matarbari power plant eyes G2G coal deal with Indonesia after quality setbacks
  • Dr Mohammad Zakir Hossain, managing director of Delta Pharma Ltd and secretary general of the Bangladesh Association of Pharmaceutical Industries (BAPI). Sketch: TBS
    Pharma industry grew with policy support, needs it again to survive: BAPI secretary general

Related News

  • Khaleda urges govt to ensure advanced treatment for singer Farida Parveen
  • Trump unveils 25% tariffs on goods from Japan, S Korea in letters to leaders
  • Japan braces for more quakes, authorities dismiss doomsday hype
  • Japan sets new internet speed record at 402Tbps using standard fibre optics
  • CA urges Japan to enhance cooperation with Bangladesh

Features

The 2020 Harrier's Porsche Cayenne coupe-like rear roofline, integrated LED lighting with the Modellista special bodykit all around, and a swanky front grille scream OEM Plus for the sophisticated enthusiast looking for a bigger family car that isn’t boring. PHOTO: Ahbaar Mohammad

2020 Toyota Harrier Hybrid: The Japanese Macan

1d | Wheels
The showroom was launched through a lavish event held there, and in attendance were DHS Motors’ Managing Director Nafees Khundker, CEO Imran Zaman Khan, and GMs Arman Rashid and Farhan Samad. PHOTO: Akif Hamid

GAC inaugurate flagship showroom in Dhaka

1d | Wheels
After India's visa restriction, China's Kunming is drawing Bangladeshi patients

After India's visa restriction, China's Kunming is drawing Bangladeshi patients

1d | Panorama
Photo: Collected/BBC

What Hitler’s tariff policy misfire can teach the modern world

2d | The Big Picture

More Videos from TBS

Apu Biswas secures bail following court surrender

Apu Biswas secures bail following court surrender

1h | TBS Today
Legal fight if 'Shapla' symbol is not given: NCP

Legal fight if 'Shapla' symbol is not given: NCP

2h | TBS Today
Prisoner sentenced to prison for not showing news of president in Tunisia

Prisoner sentenced to prison for not showing news of president in Tunisia

4h | TBS World
The price of the dollar is falling; how much can it fall?

The price of the dollar is falling; how much can it fall?

5h | TBS Stories
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2025
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net